top of page

The Science Behind the News: Ascidian Therapeutics' IND is cleared for an RNA exon editing program against Stargardt disease

blonca9
Jan 29, 2024
1 min read

Ascidian Interim President & CEO Mike Ehlers explains the scientific concept of RNA exon editing, how Stargardt as an indication is a natural fit as a proof of concept, and why he believes FDA clearance of the IND without ex-U.S. clinical data is meaningful.

Recent Posts

After exiting stealth with $20 million two weeks ago, Orchestra Bio is out to help science entrepreneurs handle the dollars and cents management and long term planning that business requires

After exiting stealth with $20 million two weeks ago, Orchestra Bio is out to help science entrepreneurs handle the dollars and cents management and long term planning that business requires

IO Biotech CEO Mai-Britt Zocca discusses the phase 3 pivotal trial result of the cancer vaccine Cylembio in first line advanced melanoma - and the company's strategy ahead

IO Biotech CEO Mai-Britt Zocca discusses the phase 3 pivotal trial result of the cancer vaccine Cylembio in first line advanced melanoma - and the company's strategy ahead

Visiting Genezen Indianpolis to see where it all started - and where the company today makes lenti and retroviral vectors for cell and gene therapies

Visiting Genezen Indianpolis to see where it all started - and where the company today makes lenti and retroviral vectors for cell and gene therapies

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

Learn more about Genezen

bottom of page